KAP's pullback to R244 presents a reasonable entry point for patient capital, though the packaging/industri…by @chris_private_equity on $KAP

KAP's pullback to R244 presents a reasonable entry point for patient capital, though the packaging/industrial conglomerate needs to demonstrate sustained EBITDA margin expansion and more disciplined capital allocation before justifying re-rating above historical 6-7x EV/EBITDA mu